Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | FES | P07332 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGAV | P06756 | 3/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.38 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.38 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034119 | 0.92 | ITGB3 (0.44) | NAMPTEGLN2EGLN1ITGB3ITGAV | |
| SCHEMBL7029649 | 0.91 | NAMPT (0.38) | NAMPTEGLN2EGLN1ITGB3ITGAV | |
| SCHEMBL7033889 | 0.91 | NAMPT (0.56) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7035562 | 0.90 | NAMPT (0.53) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7035254 | 0.90 | NAMPT (0.52) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7036085 | 0.90 | NAMPT (0.55) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7030493 | 0.89 | NAMPT (0.51) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7030829 | 0.89 | NAMPT (0.51) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7252566 | 0.89 | NAMPT (0.58) | NAMPTFESRETMARK3TYK2 | |
| SCHEMBL7035479 | 0.88 | NAMPT (0.51) | NAMPTFESRETMARK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | NAMPT 566/4885FES 4541/4885RET 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.